A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents—Amgen’s Prolia, Eli Lilly’s Forteo, and Radius Health’s Tymlos—are reserved for later lines of therapy, primarily because of their higher prices. This report presents insight into the treatment of a disease in which brands compete for market share in the second and later lines of therapy and combination use is minimal.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
  • How have Prolia, Forteo, and Tymlos been integrated into the treatment algorithm?
  • What proportion of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of osteoporosis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with osteoporosis?

Table of contents

  • Detailed, Expanded Analysis Treatment Algorithms Claims Data Analysis (US)
    • Treatment Algorithm | Osteoporosis | US | February 2019

Author(s): David Rees, Ph.D

David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.


Related Reports

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

With an increasing prevalence, due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches wil...

View Details

Osteoporosis | Unmet Need | Detailed, Expanded Analysis (US/EU)

Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that is more effective than current therapies and we...

View Details

Osteoporosis | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of osteoporosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We repo...

View Details

Osteoporosis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key osteoporosis patient p...

View Details